Skip to content

Retinal Biomarkers in Parkinson´s Disease

Retinal Biomarkers in Parkinson´s Disease: Retinal Oximetry, Pattern Electroretinography (PERG), Visual Evoked Potentials (VEP) and Optical Coherence Tomography (OCT)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06929026
Enrollment
60
Registered
2025-04-15
Start date
2023-03-10
Completion date
2026-12-31
Last updated
2025-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Retinal oximetry, Pattern Electroretinography, Visual Evoked Potentials, Optical Coherence Tomography, Oxyhemoglobin saturation

Brief summary

The goal of this observational study is to determine whether oxygen content of the retinal vessels of the eye may serve as a biomarker in Parkinson´s disease. The main questions it aims to answer are: 1. Is retinal vessel oxyhemoglobin saturation and vessel width altered in people with Parkinson´s disease? 2. Is the thickness of the retinal nerve fiber layer altered in people with Parkinson´s disease? 3. Is the response of ganglion cells of the inner retina and the visual cortex altered in people with Parkinson´s disease? The study procedure is threefold. The participants will: A. Sit in front of a screen and focus on a red dot of its middle. A simple recording electrodes are applied on the cornea, forehead and scalp for the electrophysiological measurements. Prior to this procedure a topical anesthetic gel is applied to numb the eye to prevent discomfort from placement of the corneal electrodes. B. Undergo general eye examination and optical coherence tomography (OCT) to measure the retinal tissue thickness. Prior to eye examination,eye drops are applied into the eyes to enlarge the pupils C. Sit in front of a fundus camera for obtaining images of the retinal vessels to measure oxygen saturation and the vessel width Researchers will compare the obtained measurements with age- and gender matching of healthy controls.

Interventions

None listed

Sponsors

Reykjalundur Rehabilitation
CollaboratorUNKNOWN
University of Iceland
CollaboratorOTHER
Landspitali University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Confirmed Parkinson Disease

Exclusion criteria

* Eye disease * Diabetic Mellitus * Chronic Obstructive Pulmonary Disease (COPD) * Other Neurological Disease * Smoking on a daily basis

Design outcomes

Primary

MeasureTime frameDescription
Retinal vessels oxyhemoglobin saturationBaseline. On the visit to the ambulatory Opthalamic department at LandspitaliObtained by retinal oximetry

Secondary

MeasureTime frameDescription
Vessel width of retinal arterioles and venulesBaseline. On the visit to the ambulatory Opthalamic department at LandspitaliObtained by retinal oximetry
Retinal nerve fiber layer thicknessBaseline. On the visit to the ambulatory Opthalamic department at LandspitaliObtained by cross-sectional imaging of the retinal tissue (OCT)
Components and waveform of VEPsBaseline. On the visit to the ambulatory Opthalamic department at LandspitaliPattern electroretinogram (PERG)
Pattern electroretinograms (PERGs)Baseline. On the visit to the ambulatory Opthalamic department at LandspitaliAmplitude of the visual evoked potential response

Countries

Iceland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026